CLDN5 and Alzheimer disease: To investigate whether plasma CLDN-5 protein levels change in patients with MCI and AD, we established a sensitive immunoassay system using Simoa technology and an anti-CLDN-5 mAb against the second extracellular loop domain of human CLDN-5 [16].